NY-CORSEARCH
31.1.2020 13:02:09 CET | Business Wire | Press release
Corsearch, a trademark and brand protection solutions leader, is pleased to announce the acquisition of Pointer Brand Protection, a prominent provider of anti-counterfeiting and brand protection services. The acquisition further extends Corsearch’s fast-growing brand protection offering and provides a comprehensive new service for brand owners and legal professionals. For the first time, a consolidated suite of technologically advanced solutions will support the research, clearance, monitoring, investigative, and enforcement needs of the brand lifecycle.
From counterfeiting and piracy to gray trade and brand impersonation, estimates suggest that a staggering one in four online purchases involve brand infringement. With global eCommerce expected to reach 4.5 trillion U.S. dollars by 2021, the need for online brand protection to fight these threats has never been more urgent. It is an issue that is growing in tandem with total global trade, with some reports projecting that by 2022 counterfeiting and piracy could result in the loss of 4.2 trillion U.S. dollars and the endangerment of 5.4 million legitimate jobs.
A global problem needs global solutions, and the addition of Pointer Brand Protection into the Corsearch family aligns the technological capabilities and extensive networks of the entire group into a brand establishment and protection provider with unmatched coverage.
For many businesses, the digital environment has become so complex that establishing and protecting brands is too fragmented and time consuming to be manageable. To combat this effectively, brand owners and legal professionals require technological leadership and innovative solutions to implement a strong, proactive brand protection program. The Corsearch Brand Protection platform will provide an entirely new service offering which combines the very best teams, expertise, and technologies from both Pointer and from previous Corsearch acquisition, Yellow Brand Protection. In addition to Corsearch’s existing services, the new platform will provide brands with a full-service solution combining everything from trademark research and clearing to machine learning, automated marketplace enforcement, and end-to-end investigations. To fight infringements at their source, the new team will also include the largest China-based online brand protection department in the industry.
“Since 2008, Pointer has worked with hundreds of globally-renowned brands to protect them from infringement and abuse,” said Pointer CEO, Robert Stolk. “The industry is becoming more challenging every day and brands require technologies and services that can outpace that. Joining forces with Corsearch means securing the ability to innovate in a way that anticipates the needs of customers while also benefiting from Corsearch’s trusted industry presence.”
Corsearch’s CEO, Tobias Hartmann, commented, “We are thrilled to bring the brightest minds in online brand protection together and define the future of this industry. With this strategic acquisition Corsearch becomes the only provider to support the needs of IP and brand professionals throughout the trademark lifecycle.”
About Corsearch
Corsearch (www.corsearch.com ) is a leading provider of clearance and online brand protection solutions for trademark and brand professionals. With highly trained researchers, an expansive global content set, and customer-focused technology tools available through the Corsearch platform, Corsearch empowers its customers with powerful brand solutions in an increasingly complex business environment.
Founded in 1949 and headquartered in New York, Corsearch now has over 450 employees working across its 10 global offices. Corsearch has advised 43 of the world’s top 50 brands and has in excess of 5,000 clients around the world.
For more information please contact Stephen Stolfi, Chief Commercial Officer, or visit corsearch.com.
About Pointer
Pointer Brand Protection (https://pointerbrandprotection.com/ ) has been defending global brands from counterfeiting and brand abuse since 2008. With more than 120 employees working from offices in Amsterdam, Shanghai, New York, and London, Pointer is an industry leader in the fight against brand infringement. Pointer offers holistic and bespoke anti-counterfeiting solutions that include online-to-offline investigations, test purchasing services, dedicated brand protection analysts, and a proprietary software platform for the removal of infringements. Its mission is to clean the online marketplace in order to create safety for consumers, to increase the integrity of hard-working brands, and to reduce the negative societal impact of counterfeiting.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200131005016/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
First Plus Expands Relationship with SS&C to Support Cross-Border Operations in APAC3.8.2026 03:00:00 CEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that First Plus Asset Management (FPAM), a multi-asset investment management firm, has selected SS&C to provide cross-border operations support across Asia. SS&C will service First Plus across the full investment lifecycle, delivering a scalable, integrated solution supporting transfer agency, order management and execution and investment accounting. FPAM will utilize SS&C to service its growing cross-border operating model and support around $200 million in assets under management*. “As First Plus has expanded, managing our operations has become increasingly complex,” said Jeb Li, Co-Founder and CEO at First Plus. “SS&C’s global footprint and integrated offerings enable us to easily optimize our workflows, so we can focus on scaling quickly and securely while continuing to deliver risk-adjusted returns and best-in-class client service.” The engagement highlights the breadth and scalability of SS&C’s global service model.
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 10:01:00 CEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom